Alpha-bisabolol for Onychomycosis Treatment

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Clinical, interventional, longitudinal study with random sampling. 60 patients will be divided into three groups, group A: control group, drug recommended by the Brazilian Society of Dermatology, group B: alpha bisabolol-based product associated with low-level laser therapy, and group C: alpha bisabolol based product. The topical application will be performed twice a day, while the laser application and photographs of the lesions, every 15 days. Areas of the lesions will be compared.
Epistemonikos ID: c0c5ee5a63f637c44d5e5198020baa660727dde3
First added on: May 09, 2024